Lex­i­con grabs co-pro­mo op­tion on di­a­betes drug; Shkre­li ju­ry en­ters sec­ond day of de­lib­er­a­tions

Lex­i­con Phar­ma­ceu­ti­cals $LXRX is tak­ing a co-pro­mo­tion op­tion on its SGLT 1 / 2 drug so­tagliflozin for type 1 di­a­betes. Lex­i­con plans to mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.